De Novo versus secondary metastatic EGFR-mutated non-small-cell lung cancer

• Verfasst von: Bozorgmehr, Farastuk [VerfasserIn]
• Verfasst von: Kazdal, Daniel [VerfasserIn]
• Verfasst von: Chung, Inn [VerfasserIn]
• Verfasst von: Kirchner, Martina [VerfasserIn]
• Verfasst von: Magios, Nikolaus [VerfasserIn]
• Verfasst von: Kriegsmann, Mark [VerfasserIn]
• Verfasst von: Allgäuer, Michael [VerfasserIn]
• Verfasst von: Klotz, Laura Valentina [VerfasserIn]
• Verfasst von: Muley, Thomas [VerfasserIn]
• Verfasst von: El-Shafie, Rami [VerfasserIn]
• Verfasst von: Fischer, Jürgen [VerfasserIn]
• Verfasst von: Faehling, Martin [VerfasserIn]
• Verfasst von: Stenzinger, Albrecht [VerfasserIn]
• Verfasst von: Thomas, Michael [VerfasserIn]
• Verfasst von: Christopoulos, Petros [VerfasserIn]
• Titel: De Novo versus secondary metastatic EGFR-mutated non-small-cell lung cancer
• Verf.angabe: Farastuk Bozorgmehr, Daniel Kazdal, Inn Chung, Martina Kirchner, Nikolaus Magios, Mark Kriegsmann, Michael Allgäuer, Laura V. Klotz, Thomas Muley, Rami A. El Shafie, Jürgen R. Fischer, Martin Faehling, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos
• E-Jahr: 2021
• Jahr: 09 April 2021
• Umfang: 9 S.
• Fussnoten: Gesehen am 17.05.2021
• Titel Quelle: Enthalten in: Frontiers in oncology
• Ort Quelle: Lausanne : Frontiers Media, 2011
• Jahr Quelle: 2021
• Band/Heft Quelle: 11(2021), Artikel-ID 640048, Seite 1-9
• ISSN Quelle: 2234-943X
• DOI: doi:10.3389/fonc.2021.640048
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Comutations
• Sach-SW: de novo
• Sach-SW: EGFR + NSCLC
• Sach-SW: prognosis
• Sach-SW: secondary
• K10plus-PPN: 1757909788
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Background: Metastatic epidermal growth factor receptor-mutated (EGFR)+ non-small-cell lung cancer (NSCLC) can present de novo or following previous nonmetastatic disease ("secondary"). Potential differences between these two patient subsets are unclear at present. Methods: We retrospectively analyzed characteristics of tyrosine kinase inhibitor (TKI)-treated patients with de novo vs. secondary metastatic EGFR+ NSCLC until December 2019 (n=401). Results: De novo metastatic disease was 4x more frequent than secondary (n=83/401), but no significant differences were noted regarding age (median 66 vs. 70 years), sex (65% vs. 65% females), smoking history (67% vs. 62% never/light-smokers), and histology (both greater than 95% adenocarcinoma). Patients with secondary metastatic disease showed a better ECOG performance status (PS 0-1 67%-32% vs. 46% 52%, p=0.003), fewer metastatic sites (mean 1.3 vs. 2.0, p less than 0.001), and less frequent brain involvement (16% vs. 28%, p=0.022) at the time of stage IV diagnosis. Progression-free survival (PFS) under TKI (median 17 for secondary vs. 12 months for de novo, p=0.26) and overall survival (OS, 29 vs. 25 months, respectively, p=0.47) were comparable. EGFR alterations (55% vs. 60% exon 19 deletions), TP53 mutation rate at baseline (47% vs. 43%, n=262), and T790M positivity at the time of TKI failure (51% vs. 56%, n=193) were also similar. OS according to differing characteristics, e.g. presence or absence of brain metastases (19-20 or 30-31 months, respectively, p=0.001), and ECOG PS 0 or 1 or 2 (32-34 or 20-23 or 5-7 months, respectively, p less than 0.001), were almost identical for de novo and secondary metastatic disease. Conclusions: Despite the survival advantage reported in the pre-TKI era for relapsed NSCLC, molecular features and outcome of TKI-treated metastatic EGFR+ tumors are currently independent of preceding nonmetastatic disease. This simplifies design of outcome studies and can assist prognostic considerations in everyday management of patients with secondary metastatic EGFR+ tumors.